Allied Corp. has signed a three-year sales and distribution agreement for the UK market. This comes following the expansion of Allied’s commercial team in 2023 and the recent announcement of strategic channel partnerships to enable EU-GMP manufactured products to be distributed across Europe.
According to Prohibition Partner’s 2023 European Cannabis Report, the UK market is set to become the second largest medical cannabis market in Europe after Germany. “This achievement is the result of the company’s dedication to expanding its commercial efforts in 2023 and marks a significant milestone as we are set to enter one of the most promising European markets,” says Juba Hadid, VP of Global Sales.
The sales and distribution agreement was executed between Allied, its EU-GMP Manufacturing channel partner, and a licensed medical cannabis distribution company located in the UK. Under this agreement, Allied will provide, through its EU-GMP manufacturing partner, Colombian-grown medical cannabis for a duration of 3 years from the date of signing with the option to renew for subsequent years. This agreement details the provisions of the supply partnership into the territory, including specified minimum monthly order quantities and a yearly volume commitment.
For more information:
Allied Corp
allied.health